Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Other financing activities (2020)

Larimar Therapeutics (LRMR) has disclosed Other financing activities for 3 consecutive years, with $473000.0 as the latest value for Q1 2015.

  • For the quarter ending Q1 2015, Other financing activities fell 42.81% year-over-year to $473000.0, compared with a TTM value of $473000.0 through Dec 2015, down 79.54%, and an annual FY2018 reading of $312000.0, changed N/A over the prior year.
  • Other financing activities was $473000.0 for Q1 2015 at Larimar Therapeutics, down from $894000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $894000.0 in Q3 2014 and bottomed at $31000.0 in Q4 2013.
  • Average Other financing activities over 3 years is $563200.0, with a median of $591000.0 recorded in 2014.
  • Peak annual rise in Other financing activities hit 42.81% in 2015, while the deepest fall reached 42.81% in 2015.
  • Year by year, Other financing activities stood at $31000.0 in 2013, then skyrocketed by 2783.87% to $894000.0 in 2014, then plummeted by 47.09% to $473000.0 in 2015.
  • Business Quant data shows Other financing activities for LRMR at $473000.0 in Q1 2015, $894000.0 in Q3 2014, and $591000.0 in Q2 2014.